Manchester and London, UK, 15 July, 2014 – C4X Discovery (C4XD), a leader in rational drug discovery and design, today announced that its patent relating to a new method for determining the three-dimensional structures of dynamic molecules has been granted in Japan.
C4XD has the only technology in the world that can generate accurate, experimentally-derived dynamic solution 3D structures of drug molecules in just a matter of days. It can be used in conjunction with existing technologies for structure-based drug design, and can make a particularly high impact when protein crystallography is not routinely available, as is the case for GPCRs and ion channels.
The granting of this patent by the Japan Patent Office marks an important step in C4XD’s development. The patent covers a core element of the C4XD platform for determination of dynamic molecular structures in solution. The patent has been filed in other major territories including the United States and Europe.
Dr Andrew Almond, CTO and co-founder of C4XD, said “This is excellent recognition of our inventive approach and its unique ability to accurately determine the dynamic 3D structures of molecules. In the next couple of years, we expect to build extensively on this core patent position as we apply the technology to the identification of multiple novel agents against high-value therapeutic disease targets.”
Dr Charles Blundell, CSO and co-founder of C4XD, added “This is an important next step in establishing and validating the uniqueness of the C4XD approach, and in protecting the intellectual property assets of the Company.”
For further information please contact:
C4X Discovery Ltd
Piers Morgan, CEO
07912 293832
John Dineen, FTI
020 3727 1136
comms@c4xdiscovery.com
About C4X Discovery Ltd
C4X Discovery is a Manchester-based company focused on optimising drug discovery and design. It was founded in 2008 as a spin-out from the University of Manchester. The company uses its NMR-based technology to solve the dynamic 3D structures of a broad range of biomolecules, including peptides, cofactors, oligonucleotides and carbohydrates. Since C4X Discovery’s NMR technology shows what shapes active molecules prefer to adopt, it provides high-quality templates for drug discovery and design, and valuable information for drug candidate optimisation. In addition, the data is generated faster and more reliably than standard techniques such as X-ray co-crystallography or molecular modelling. C4X Discovery is using its technology in collaboration with the pharmaceutical industry and to build its own proprietary pipeline of high-value therapeutic candidates. It has been funded since inception by life science investor Aquarius Equity Partners. www.c4xdiscovery.com .
Help employers find you! Check out all the jobs and post your resume.
